Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what the timetable is for Tafamadis to be made available on the NHS for people with hereditary cardiac amyloidosis.

The National Institute for Health and Care Excellence (NICE) is the independent body that makes evidence-based recommendations for the National Health Service on whether new medicines should be routinely funded based on an assessment of their clinical and cost effectiveness. NICE published guidance in May 2021 that does not recommend tafamidis for the treatment of wild-type or hereditary transthyretin amyloidosis with cardiomyopathy in adults. NHS England and NHS Improvement do not therefore routinely commission tafamidis for NHS patients in England. Where a treatment is not routinely commissioned by the NHS, a patient’s clinician may submit an individual funding request if they consider it is in their patient’s best interests to have that treatment.